title: [Hypertricglyceridemia: prognostic impact and treatment options].
abstract: Elevated Triglyceride levels are associated with increased risk for atherosclerotic disease and additional vascular risk factors such as obesity, hypertension and impaired glucose tolerance. To estimate the individual cardiovascular risk of a patient with elevated triglycerides LDL- and HDL-cholesterol levels, concomitant diseases, composition of triglyceride rich lipoproteins and a family history for premature coronary heart disease are important. Primary goals for the management of hypertriglyceridemia are a reduction of cardiovascular risk and prevention of triglyceride associated complications such as the chylomicronemia syndrome. The basis of treatment are lifestyle changes: dietary intervention, alcohol avoidance, regular physical activity, weight loss and smoking cessation to modify risk factors. If triglyceride levels can not be sufficiently reduced by lifestyle intervention pharmacotherapy (nicotinic acid, fibrates and omega-3-acid ethyl esters) is indicated. Beyond reduction of triglyceride levels optimization of non-HDL-cholesterol by statin treatment is warranted to reduce vascular risk.
authors.affiliation: Klinik für Innere Medizin III, Kardiologie, Angiologie und internistische Intensivmedizin, Universitätsklinikum des Saarlandes. florian.custodis@uks.eu
authors.forename: F
authors.initials: F
authors.lastname: Custodis
authors.forename: U
authors.initials: U
authors.lastname: Laufs
mesh_terms: D000328:Adult; D002318:Cardiovascular Diseases / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000517:prevention & control*; D004038:Diet, Reducing; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000175:diagnosis / Q000235:genetics / Q000628:therapy; D015228:Hypertriglyceridemia / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D008019:Life Style; D008297:Male; D009525:Niacin / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood; D015431:Weight Loss
chemical_list: D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides; D009525:Niacin